Trillium Therapeutics Inc (TRIL)

[NY1972]

Value of a IO drug for treating patients with newly diagnosed, or first-line lung.

Bristol shares plummeted 19%, or a loss of $24 billion in market value, in premarket trading on the Opdivo disappointment.

Merck's stock price shot up 11%, a gain of nearly $18 billion in market value, in reaction because the Opdivo setback is seen as a win for the company's competing checkpoint inhibitor Keytruda.

https://www.thestreet.com/story/13666312/1/bristol-myers-plunges-on-shocking-cancer-immunotherapy-lung-cancer-study-failure.html?puc=yahoo&cm_ven=YAHOO